Decay kinetics of human immunodeficiency virus-specifiic effector cytotoxic T lymphocytes after combination antiretroviral therapy

Journal of Virology

Volumn 73, Issue 1, 1999, Pages 797-800

  Ogg, G S ^a   Jin, X ^c   Bonhoeffer, S ^a   Moss, P ^b   Nowak, M A ^c   Monard, S ^c   Segal, J P ^c   Cao, Y ^c   Rowland Jones, S L ^a   Hurley, A ^c   Markowitz, M ^c   Ho, D D ^c   McMichael, A J ^a   Nixon, D F ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b School of Natural Sciences   (United Kingdom)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; NELFINAVIR; RITONAVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; STRAIN DIFFERENCE; T LYMPHOCYTE ACTIVATION; VIREMIA;

EID: 0006922163     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.1.797-800.1999     Document Type: Article

References (24)

1. Ahmed, R., and D. Gray. 1996. Immunological memory and protective immunity: understanding their relation. Science 272:54-60.
2. Altman, J., P. A. H. Moss, P. Goulder, et al. 1996. Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infected individuals. Science 274:94-96.
3. + homeostasis and function in advanced HIV disease. Science 277:112-116.
4. + lymphocyte responses to antiretroviral therapy of HIV infection. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 13:320-326.
5. Dorrell, L., T. Dong, G. S. Ogg, et al. Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa. J. Virol., in press.
6. 5a.Dyer, W. B., G. S. Ogg, M. A. Demoitie, X. Jin, A. F. Geczy, S. L. Rowland-Jones, A. J. McMichael, D. F. Nixon, J. S. Sullivan. 1999. Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1. 73:436-443.
7. Ehl, S., P. Klenerman, P. Aichele, et al. 1997. A functional and kinetic comparison of antiviral effector and memory cytotoxic T lymphocyte populations in vivo and in vitro. Eur. J. Immunol. 27:3404-3413.
8. Giorgi, J., and R. Detels. 1989. T cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS Cohort Study. Clin. Immunol. Immunopathol. 52:10-18.
9. Gotch, F. M., D. F. Nixon, N. Alp, et al. 1990. High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals. Int. Immunol. 2:707-711.
10. Goulder, P. J. R., A. K. Sewell, D. G. Lalloo, et al. 1997. Patterns of Immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigen (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J. Exp. Med. 185:1423-1433.
11. Ho, D. D. 1998. Towards HIV eradication or remission: the task ahead. Science 280:1866.
12. 10a.Jin, X., et al. Unpublished data.
13. Kelleher, A. D., A. Carr, J. Zaunders, and D. A. Cooper. 1996. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J. Infect. Dis. 173:321-329.
14. + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 16:83-92.
15. Moss, P. A. H., S. L. Rowland-Jones, P. M. Frodsham, et al. 1995. Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. Proc. Natl. Acad. Sci. USA 92:5773-5777.
16. Murali-Krishna, K., J. D. Altman, M. Suresh, et al. 1998. Counting antigen-specific CD8 T cells: a re-evaluation of bystander activation during viral infection. Immunity 8:177-187.
17. Nowak, M. A., S. Bonhoeffer, G. M. Shaw, and R. M. May. 1997. Antiviral drug treatment: dynamics of resistance in free virus and infected cell populations. J. Theor. Biol. 184:203-217.
18. Ogg, G., X. Jin, S. Bonhoeffer, et al. 1998. Quantitation of HIV-specific CTL and plasma load of viral RNA. Science 279:2103-2106.
19. Parker, K. C., M. A. Bednarek, L. K. Hull, et al. 1992. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J. Immunol. 149:3580-3587.
20. + T cell responses associated with control of viremia. Science 278:1447-1450.
21. Shiga, H., T. Shioda, H. Tomiyama, et al. 1996. Identification of multiple HIV-1 cytotoxic T-cell epitopes presented by human leukocyte antigen B35 molecules. AIDS 10:1075-1083.
22. Shubinsky, G., and M. Schlesinger. 1997. The CD38 lymphocyte differentiation marker: new insight into its ectoenzymatic activity and its role as a signal transducer. Immunity 7:315-324.
23. + T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc. Natl. Acad. Sci. USA 88:11276-11280.
24. + T cells in chronic HIV infection are antigen-specific. J. Exp. Med. 188:785-790.